L
Lanxiang Huang
Researcher at Wuhan University
Publications - 10
Citations - 262
Lanxiang Huang is an academic researcher from Wuhan University. The author has contributed to research in topics: Biology & Tumor microenvironment. The author has an hindex of 3, co-authored 6 publications receiving 28 citations.
Papers
More filters
Journal ArticleDOI
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer
Lanxiang Huang,Yuan Rong,Xuan Tang,Kezhen Yi,Peng Qi,Jinxuan Hou,Weihuang Liu,Yuan He,Xing Gao,Chunhui Yuan,Fu-Bing Wang +10 more
TL;DR: HELA-Exos as discussed by the authors is an in situ dendritic cell (DC) vaccine for breast cancer, which can be applied to various types of cancers. But, it is not suitable for use in the treatment of cancer patients.
Journal ArticleDOI
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer
Lanxiang Huang,Yuan Rong,Xuan Tang,Kezhen Yi,Peng Qi,Jinxuan Hou,Weihuang Liu,Yuan He,Xing Gao,Chunhui Yuan,Fu-Bing Wang +10 more
TL;DR: HELA-Exos as discussed by the authors is an in situ dendritic cell (DC) vaccine for breast cancer, which can be applied to various types of cancers. But, it is not suitable for use in the treatment of cancer patients.
Journal ArticleDOI
Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications.
TL;DR: The use of CTCs to assess the progression of hepatocellular carcinoma (HCC) is discussed and the progress in single-cell based analysis and preclinical modeling of the pattern and kinetics of C TCs is reviewed.
Journal ArticleDOI
SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies.
Lanxiang Huang,Yuan Rong,Qin Pan,Kezhen Yi,Xuan Tang,Qian Zhang,Wei Wang,Jianyuan Wu,Fu-Bing Wang +8 more
TL;DR: The status of the development of coronavirus vaccines is presented, focusing particularly on the biomimetic nanoparticle technology platform, which is likely to have a major role in future developments of personalized medicine.
Journal ArticleDOI
Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells.
Yuan Rong,Lanxiang Huang,Kezhen Yi,Hao Chen,Shao-Ping Liu,Wu-Wen Zhang,Chun-Hui Yuan,Xue-Min Song,Fu-Bing Wang +8 more
TL;DR: Co-administration of SFN and DOX was more efficacious for the treatment of breast cancer in a mouse model than either agent alone, as evidenced by the significant decrease in tumor volume, MDSC expansion, and increase in cytotoxic CD8+ T cells.